Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a humanized IgG4 recombinant monoclonal antibody that binds to programmed death receptor-1 (PD-1) and prevents the interaction with its ligands PD-L1 and PD-L2. This results in the activation of T-cell mediated immune response and inhibits tumor cell growth. The original drug received approval in China in 2018 as the second line of treatment for melanoma. Currently, the drug is evaluated for efficacy and toxicity in Phase I-III clinical trials for nasopharyngeal carcinoma, head and neck squamous cell carcinoma and gastric adenocarcinoma
Biovision | A2161 | Anti-PD-1 (Toripalimab), Humanized Antibody DataSheet
Antibody Target: PD-1
Target Alternative Name: JS001, Tab001, PD1, PDCD1, CD279, SLEB2, hPD-1, hPD-l, hSLE1
Tag Line: The biosimilar is a humanized monoclonal antibody that binds to PD-1 and prevents the association with its ligands PD-L1 and PD-L2, thus activating T-cell mediated immune response and inhibiting tumor growth
Category: Biosimilars
Host: Recombinant
Isotype: IgG4, kappa
Species Reactivities: Human
Immunogen Sequence: Human PD-1
Accession #: DB15043
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
